In the United States alone, there are an estimated 20,000 people living with amyotrophic lateral sclerosis (ALS), also called as Lou Gehrig's disease. The fatal disease destroys the nerve cells which control breathing, walking, and eating. Very few people survive more than three years after being diagnosed.
Lou Gehrig disease which has no cure is finally seeing a ray of hope by Tel Aviv University researchers. The disease also called Amyotrophic lateral sclerosis (ALS) a neurodegenerative issue which causes muscles to atrophy and produces permanent disability in patients. The investigators say they may have found the basis of what could become a treatment for the devastating disease.
Sangamo Therapeutics, Inc. and Pfizer Inc. announced a collaboration for the development of a potential gene therapy using zinc finger protein transcription factors to treat amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) linked to mutations of the C9ORF72 gene.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.